Skip to main content

Nautilus Biotechnology, Inc. (NAUT)

NASDAQ: NAUT · IEX Real-Time Price · USD
5.10
-0.04 (-0.78%)
After-hours:Oct 22, 2021 6:10 PM EDT
5.14
-0.30 (-5.51%)
At close: Oct 22, 4:00 PM
Market Cap645.33M
Revenue (ttm)n/a
Net Income (ttm)-31.80M
Shares Out55.07M
EPS (ttm)-1.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume862,087
Open5.40
Previous Close5.44
Day's Range5.11 - 5.40
52-Week Range5.11 - 12.38
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 2, 2021

About NAUT

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.

IndustryBiotechnology
Founded2016
Employees89
Stock ExchangeNASDAQ
Ticker SymbolNAUT
Full Company Profile

Financial Performance

Financial Statements

News

Nautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021

SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, toda...

1 week ago - GlobeNewsWire

Nautilus to Participate in the Morgan Stanley Global Healthcare Conference

SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteom...

1 month ago - GlobeNewsWire

3 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Other symbols:CRCTMYOV
1 month ago - Benzinga

Nautilus Biotechnology Reports Second Quarter 2021 Financial Results

SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a life sciences company creating a platform technology for quantifying and unlocking the complexity...

2 months ago - GlobeNewsWire

Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development

Former Pacific Biosciences executive brings deep expertise in single-molecule analysis to large-scale platform designed to comprehensively quantify the proteome Former Pacific Biosciences executive brin...

2 months ago - GlobeNewsWire

Why Nautilus Biotechnology (NAUT) Stock Trading Higher Thursday?

Nautilus Biotechnology Inc (NASDAQ: NAUT) shares are trading higher during mid-day trading on Thursday following a CNBC report that Amazon.com Inc (NASDAQ: AMZN) held around $15 million stake in the com...

Other symbols:NLS
2 months ago - Benzinga

Nautilus Biotechnology shares surge 50% on news of Amazon investment

Shares of Nautilus Biotechnology rose by as much as 50% on Thursday morning after a report revealed that Amazon has taken an equity stake in the newly public Seattle-based company.

Other symbols:NLS
2 months ago - GeekWire

Amazon discloses investment in biotech firm Nautilus

CNBC's Dominic Chu reports on an Amazon invetment of $14.7 million in Nautilus, a pre-revenue biotech firm.

Other symbols:AMZN
2 months ago - CNBC Television

Amazon invested millions in a pre-revenue company with a system for measuring human proteins

Amazon declined to specify whether it's working with Nautilus Technology in addition to investing. The online retailer has been pushing into health care.

Other symbols:AMZN
2 months ago - CNBC

Nautilus Biotechnology to Announce Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021

SEATTLE, July 13, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, toda...

3 months ago - GlobeNewsWire

Sujal Patel-led Nautilus Biotechnology goes public as it tackles ambitious plan to analyze proteins

Nautilus Biotechnology is emerging as Seattle's newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biom...

4 months ago - GeekWire

Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Pro...

SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the c...

4 months ago - GlobeNewsWire

ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III (“ARYA”) (Nasdaq: ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COV...

4 months ago - GlobeNewsWire

Nautilus Biotechnology Appoints Matt Murphy as General Counsel

SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)--Nautilus Biotechnology appoints Matt Murphy, former 10x Genomics and Pacific Biosciences executive, as General Counsel

6 months ago - Business Wire

SHAREHOLDER ALERT: WeissLaw LLP Investigates Arya Sciences Acquisition Corp. III

NEW YORK, Feb. 9, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arya Sciences Acquisition Corp. III ("AR...

8 months ago - PRNewsWire

Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Co...

SEATTLE & NEW YORK--(BUSINESS WIRE)--Nautilus Biotechnology, Inc. ("Nautilus Biotechnology" or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human pro...

8 months ago - Business Wire